drug
tisagenlecleucel
Marketedupdated 5mo agoby $NVS NOVARTIS AG
Approvedcommunity read0 votes
indications
investigational
DLBCL
all catalysts(0)
nothing on the calendar yet
Trials studying tisagenlecleucel
- —Long-term Follow up Local Registry Study of Kymriah in South Korea
- phase2Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma
- phase3A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
- phase3Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
- phase2A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)
- phase2Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- phase1Tisagenlecleucel In Primary CNS Lymphoma
- phase1Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
News(3)
- Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEOEric Cantor, who represented Virginia in the U.S. House of Representatives for 14 years and served as House majority leader from 2011 to 2014, will step up as PhRMA’s next president and CEO on Nov.…fiercebiotech · 7d ago
- Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdleSafety will be the key determinant of in vivo CAR T therapies, according to H.C. Wainwright’s Mitchel Kapoor, who noted that convenience and efficacy won’t be enough to impress investors in this sp…biospace · 2mo ago
- Legend surges on early data for ‘in vivo’ lymphoma cell therapyInitial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with “ex vivo” medicines like Novartis’ Kymriah.biopharma_dive · 4mo ago
Data sources
last refreshed 6h ago
Found something off?
comments(0)
5-min edit window · permanent after that